Tenax Therapeutics, Inc. (TENX) News
Filter TENX News Items
TENX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TENX News From Around the Web
Below are the latest news stories about TENAX THERAPEUTICS INC that investors may wish to consider to help them evaluate TENX as an investment opportunity.
TENX: IND Clears Way for Phase IIIBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) |
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory BoardCHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Butler to our Scientific Advisory Board,” said Stuart Rich, M.D., |
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?Although Tenax Therapeutics has received a green light for its investigational drug, investors should exercise caution with TENX stock. |
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)FDA agreement that 6MWD will be the primary endpoint for both Phase 3 studies Phase 3 program designed to satisfy FDA’s request for subject drug exposure of 300 patients for 6 months, 100 patients for 1 year (minimum requirements per ICH guidelines)No FDA requirement for a cardiovascular outcomes trial Oral levosimendan use in PH-HFpEF is protected by USPTO granted patent that will not expire until the end o |
TENX: Second Quarter ResultsBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 2Q:23 results on August 14, 2023 via its filing of Form 10-Q with the SEC. Despite the slow pace of advancement, we are impressed with the clinical data for both of Tenax’ PAH assets: levosimendan and imatinib. We see tremendous |
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot PoleThere are some solid biotech stocks on the market. |
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are currently no FDA-approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030Broadens Tenax’s U.S. IP protection for a market with the potential to generate billions in future estimated annual salesLevosimendan is the only drug to show statistically |
TENX: Notice of Allowance Increases ConfidenceBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Additional Support for Oral Levosimendan Tenax Therapeutics, Inc. (NASDAQ:TENX) announced that the US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for its patent covering the use of oral levosimendan in pulmonary hypertension in patients with heart failure and preserved ejection fraction (PH-HFpEF). |
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030Once granted, this patent will significantly broaden Tenax’s U.S. intellectual property (IP) protection for a market with the potential to |
TENX: Prioritizing LevosimendanBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT First Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 1Q:23 results on May 15, 2023 via its filing of Form 10-Q with the SEC. Despite the slow pace of advancement, we are impressed with the clinical data for both of Tenax’ PAH assets: levosimendan and imatinib. We see tremendous |